Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Fulgent Genetics, Inc.NASDAQ: FLGT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$19.96M, compared with -$5.79M a year earlier. Trailing-twelve-month EBITDA was -$58.51M.
Context
- EBITDA amounted to 14.2% of revenue in FY2025, up 4.7 pp from a year earlier.
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of -$28.18M (+38.5%) for the fiscal year ending Dec 2026, a step up from the -70.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$19.96M+13.3% QoQ
- Last fiscal yearDec 2025
- -$45.83M-70.6% YoY
- LTMMar 2026
- -$58.51M-133.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -244.7% | +67.7% | +312.5 pp |
| 1 year | -70.6% | +38.5% | +109.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (45.83M) USD
- Year-over-year change
- -70.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (45.83M) | -70.6% |
| FY2024 | 2024-12-31 | (26.86M) | +81.8% |
| FY2023 | 2023-12-31 | (147.45M) | -167.7% |
| FY2022 | 2022-12-31 | 217.7M | -68.5% |
| FY2021 | 2021-12-31 | 692.04M | — |
EBITDA vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 EBITDA of -$58.51M is the 3rd highest of the 8 companies compared; the peer median is -$85.53M.
- Its year-over-year change of -133.4% is the 6th highest of 8, against a peer median of -16.7%.
- EBITDA amounts to 18.3% of revenue for FLGT, versus a peer median of 16.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BLLNBillionToOne, Inc. | LTM Jun 2026 | $50.25M | +362.6% | — | 12.6% |
| LTM Jun 2026 | $12.89M | +145.3% | — | 1.7% | |
| LTM Mar 2026 | -$58.51M | -133.4% | — | 18.3% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | -$76.43M | -374.1% | — | 16.8% |
| LTM Mar 2026 | -$85.53M | -16.7% | — | 132.6% | |
| LTM Jun 2026 | -$178.71M | +15.6% | — | 6.6% | |
| LTM Mar 2026 | -$334.2M | -423.0% | — | 40.3% | |
| LTM Sep 2026 | -$441.45M | -24.7% | — | 34.5% | |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | -$85.53M | -16.7% | — | 16.8% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 992.58M | 618.97M | 289.21M | 283.47M | 322.67M |
| Cost of Revenue | 215.53M | 252.07M | 184.76M | 176.26M | 191.8M |
| Gross Profit | 777.05M | 366.9M | 104.46M | 107.22M | 130.88M |
| Gross Margin | 78.3% | 59.3% | 36.1% | 37.8% | 40.6% |
| Research & Development | 24.22M | 28.91M | 41.44M | 48.82M | 53.91M |
| Selling, General & Admin | 75.17M | 149.99M | 130.47M | 124.35M | 160.04M |
| Operating Expenses | 101.1M | 188.37M | 299.99M | 181.13M | 221.97M |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| EBITDA | 692.04M | 217.7M | (147.45M) | (26.86M) | (45.83M) |
| EBITDA Margin | 69.7% | 35.2% | -51.0% | -9.5% | -14.2% |
| Operating Income | 675.95M | 178.53M | (195.53M) | (73.92M) | (91.1M) |
| Operating Margin | 68.1% | 28.8% | -67.6% | -26.1% | -28.2% |
| Interest Income | 1.35M | 5.62M | 21.61M | 31.3M | 30.92M |
| Interest Expense | 0 | 1.01M | 488K | 170K | 75K |
| Other Income / Expenses | 5.08M | 5.5M | 21.44M | 21.96M | 21.07M |
| Income Before Tax | 681.03M | 184.03M | (174.09M) | (51.96M) | (70.03M) |
| Pre-Tax Margin | 68.6% | 29.7% | -60.2% | -18.3% | -21.7% |
| Income Tax Expense | 174.8M | 42.1M | 1.15M | (8.14M) | (8.39M) |
| Net Income | 507.36M | 143.4M | (167.83M) | (42.71M) | (60.51M) |
| Net Margin | 51.1% | 23.2% | -58.0% | -15.1% | -18.8% |
| EPS (Basic) | 17.13 | 4.76 | (5.63) | (1.41) | (1.97) |
| EPS (Diluted) | 16.26 | 4.63 | (5.63) | (1.41) | (1.97) |
| Weighted Avg Shares | 29.41M | 30.1M | 29.78M | 30.24M | 30.78M |
| Weighted Avg Shares (Diluted) | 30.98M | 30.96M | 29.78M | 30.24M | 30.78M |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.